**Supplemental Digital Content 2**

Supplementary results: description of medications

**Supplementary results**

**Table S1. Distribution of pulmonary and cardiovascular medications in patients with COPD and Controls.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **COPD** |  | **Controls** |
| **Pulmonary Medications** |  |  |  |
| Long-acting β2-agonist | 8 |  | 0 |
| Long-acting anticholinergic  bronchodilator | 8 |  | 0 |
| Short-acting anticholinergic  bronchodilator | 3 |  | 0 |
| Glucocorticoid | 7 |  | 0 |
| Theophylline | 1 |  | 0 |
| *No. of subjects on pulmonary medication* | *10/10* |  | *0/10* |
| **Cardiovascular Medications** |  |  |  |
| β blocker | 3 |  | 0 |
| α-agonist | 0 |  | 1 |
| ACE inhibitor | 2 |  | 0 |
| Ca+ channel blocker | 1 |  | 0 |
| Diuretic | 2 |  | 0 |
| Statin | 2 |  | 1 |
| *No. of subjects on anti-hypertensive medication* | *5/10* |  | *1/10* |